ENDOCRINE TUMOURS: Genetic predictors of thyroid cancer outcome.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  European Journal of Endocrinology

• Publication date

  2016-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1530/EJE-15-0605PMID 26510840
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Telomerase in differentiated thyroid cancer: promoter mutations, expression and localization.

  2015cited by this paper
• The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer

  2015cited by this paper
• Coexistence of TERT promoter and BRAF mutations in papillary thyroid carcinoma: added value in patient prognosis?

  2015cited by this paper
• Cancer-associated TERT promoter mutations abrogate telomerase silencing

  2015cited by this paper
• TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma.

  2015cited by this paper
• TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.

  2014cited by this paper
• TERT Promoter Mutations Are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas

  2014cited by this paper
• BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.

  2014cited by this paper
• Prognostic biomarkers in thyroid cancer

  2014cited by this paper
• Noncoding RNAs in endocrine malignancy.

  2014cited by this paper
• Cell cycle deregulation and TP53 and RAS mutations are major events in poorly differentiated and undifferentiated thyroid carcinomas.

  2014cited by this paper
• The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas

  2014cited by this paper
• Integrated genomic characterization of papillary thyroid carcinoma.

  2014cited by this paper
• NRAS Codon 61 Mutation Is Associated with Distant Metastasis in Patients with Follicular Thyroid Carcinoma

  2014cited by this paper
• PAX8/PPARγ Rearrangement in Thyroid Nodules Predicts Follicular-Pattern Carcinomas, in Particular the Encapsulated Follicular Variant of Papillary Carcinoma

  2014cited by this paper
• RAS mutations in thyroid cancer.

  2013cited by this paper
• Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.

  2013cited by this paper
• Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer.

  2013cited by this paper
• Aumento della captazione del radioiodio indotto da selumetinib in pazienti con cancro della tiroide

  2013cited by this paper
• Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.

  2013cited by this paper
• Cribriform-Morular Variant of Papillary Thyroid Carcinoma Displaying Poorly Differentiated Features

  2013cited by this paper
• Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.

  2013cited by this paper
• Highly prevalent TERT promoter mutations in aggressive thyroid cancers.

  2013cited by this paper
• TERT Promoter Mutations in Familial and Sporadic Melanoma

  2013cited by this paper
• Frequency of TERT promoter mutations in human cancers

  2013cited by this paper
• The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study.

  2012cited by this paper
• RET/PTC rearrangement is prevalent in follicular Hürthle cell carcinomas

  2012cited by this paper
• The Associations Between RAS Mutations and Clinical Characteristics in Follicular Thyroid Tumors: New Insights from a Single Center and a Large Patient Cohort

  2012cited by this paper
• RET/PTC Translocations and Clinico-Pathological Features in Human Papillary Thyroid Carcinoma

  2012cited by this paper
• TGF-beta/Smad pathway and BRAF mutation play different roles in circumscribed and infiltrative papillary thyroid carcinoma

  2012cited by this paper
• A comparative study of cell cycle mediator protein expression patterns in anaplastic and papillary thyroid carcinoma

  2012cited by this paper
• MicroRNA as a diagnostic tool in fine-needle aspiration biopsy of thyroid nodules.

  2012cited by this paper
• The polymorphism rs944289 predisposes to papillary thyroid carcinoma through a large intergenic noncoding RNA gene of tumor suppressor type

  2012cited by this paper
• The biology and the genetics of Hurthle cell tumors of the thyroid.

  2012cited by this paper
• Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.

  2011cited by this paper
• The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases

  2011cited by this paper
• Genetic Alterations in Poorly Differentiated and Undifferentiated Thyroid Carcinomas

  2011cited by this paper
• Telomere length in neoplastic and nonneoplastic tissues of patients with familial and sporadic papillary thyroid cancer.

  2011cited by this paper
• Molecular genetics and diagnosis of thyroid cancer

  2011cited by this paper
• RET rearrangements and BRAF mutation in undifferentiated thyroid carcinomas having papillary carcinoma components

  2010cited by this paper
• p53 Research: the past thirty years and the next thirty years.

  2010cited by this paper
• High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas

  2009cited by this paper
• The first 30 years of p53: growing ever more complex

  2009cited by this paper
• Cribriform-morular variant of papillary thyroid carcinoma: molecular characterization of a case with neuroendocrine differentiation and aggressive behavior.

  2009cited by this paper
• Intragenic mutations in thyroid cancer.

  2008cited by this paper
• BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.

  2008cited by this paper
• BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.

  2008cited by this paper
• Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis

  2007cited by this paper
• BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism.

  2007cited by this paper
• The Prevalence and Prognostic Value of BRAF Mutation in Thyroid Cancer

  2007cited by this paper
• Different structural components of conventional papillary thyroid carcinoma display mostly identical BRAF status

  2007cited by this paper
• The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane.

  2006cited by this paper
• The BRAF mutation is useful for prediction of clinical recurrence in low‐risk patients with conventional papillary thyroid carcinoma

  2006cited by this paper
• PAX8-PPARγ rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma

  2006cited by this paper
• PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma.

  2006cited by this paper
• Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature.

  2006cited by this paper
• Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation.

  2005cited by this paper
• BRAFE600-associated senescence-like cell cycle arrest of human naevi

  2005cited by this paper
• BRAF mutation in thyroid cancer.

  2005cited by this paper
• Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations

  2005cited by this paper
• The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells.

  2005cited by this paper
• Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients’ age but not with tumour aggressiveness

  2005cited by this paper
• Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hürthle cell) tumours of the thyroid

  2005cited by this paper
• BRAF mutations in an Italian cohort of thyroid cancers

  2004cited by this paper
• Telomere erosion triggers growth arrest but not cell death in human cancer cells retaining wild-type p53: implications for antitelomerase therapy

  2004cited by this paper
• Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers.

  2003cited by this paper
• Genomic DNA Extraction and PCR Amplification of Exon 15 of the BRAF Gene and Exons 1 and 2 of the NRAS Gene

  2003cited by this paper
• ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer.

  2003cited by this paper
• BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas.

  2003cited by this paper
• Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations.

  2003cited by this paper
• RET/PTC rearrangement in thyroid tumors

  2002cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas.

  2002cited by this paper
• bcl2, p53 and bax in thyroid tumors and their relation to apoptosis.

  2001cited by this paper
• Squamous Cell Carcinoma of the Thyroid: An Aggressive Tumor Associated with Tall Cell Variant of Papillary Thyroid Carcinoma

  2000cited by this paper
• MIXED COLUMNAR CELL AND TALL CELL VARIANT OF PAPILLARY CARCINOMA OF THYROID: A CASE REPORT AND REVIEW OF THE LITERATURE

  2000cited by this paper
• Oncogene profile of papillary thyroid carcinoma.

  1999cited by this paper
• High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET/PTC3 and the solid-follicular variant.

  1999cited by this paper
• Sporadic ret‐rearranged papillary carcinoma of the thyroid: a subset of slow growing, less aggressive thyroid neoplasms?

  1998cited by this paper
• Prevalences of Gsα, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population

  1998cited by this paper
• p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells

  1997cited by this paper
• Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children.

  1997cited by this paper
• Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident.

  1996cited by this paper
• Overexpression of p53 in tall cell variants of papillary thyroid carcinoma.

  1996cited by this paper
• A Novel Panel of Antibodies that Segregates Immunocytochemically Poorly Differentiated Carcinoma from Undifferentiated Carcinoma of the Thyroid Gland

  1994cited by this paper
• Immunohistochemical detection of p53 in differentiated, poorly differentiated and undifferentiated carcinomas of the thyroid

  1994cited by this paper
• Overexpression of p53 as a Possible Prognostic Factor in Human Thyroid Carcinoma

  1993cited by this paper
• Genetic Alterations in Thyroid Tumor Progression: Association with p53 Gene Mutations

  1993cited by this paper
• High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.

  1993cited by this paper
• Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland.

  1993cited by this paper
• Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland.

  1992cited by this paper
• Mutation of the p53 gene in a differentiated human thyroid carcinoma cell line, but not in primary thyroid tumours.

  1991cited by this paper
• A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases

  1987cited by this paper

• Tracing the molecular route to progression in miRNA-biogenesis-defective thyroid lesions

  2026cites this paper
• Somatic genetic alterations in the development and progression in thyroid tumors of follicular cells

  2025cites this paper
• Molecular Diagnostics and Personalized Therapeutics in Differentiated Thyroid Carcinoma: A Clinically Oriented Review

  2025cites this paper
• Challenges of the 5th Edition of the WHO Classification of Thyroid Tumours

  2025cites this paper
• Exploring MAPK and mTOR Pathways in Feline Thyroid Tumors

  2025cites this paper
• Short Term Outcome of Radioactive Iodine Ablation Therapy in Patients of Papillary Thyroid Carcinoma with B-RAF Mutation

  2025cites this paper
• Insights in biomarkers complexity and routine clinical practice for the diagnosis of thyroid nodules and cancer

  2025cites this paper
• TP53 Alterations Associate with Poor Response to Lenvatinib in Patients with Advanced Thyroid Cancer.

  2025cites this paper
• TERT RNAscope analysis of sub-centimetric papillary thyroid carcinomas and synchronous lymph node metastases

  2024cites this paper
• Demographic and Prognostic Factors of the Columnar Cell Variant of Papillary Thyroid Carcinoma: A National Cancer Database Study

  2024cites this paper
• Association between thyroid disorders and extra-thyroidal cancers, a review

  2024cites this paper
• Identification of BRAF, CCND1, and MYC mutations in a patient with multiple primary malignant tumors: a case report and review of the literature

  2023cites this paper
• Molecular testing for thyroid nodules: Where are we now?

  2023cites this paper
• Advances in the management of anaplastic thyroid carcinoma: transforming a life-threatening condition into a potentially treatable disease

  2023cites this paper
• Molecular testing raises thyroid nodule fine needle aspiration diagnostic value

  2023cites this paper
• Genetic and clinical profiles of 160 papillary thyroid cancers with lateral neck lymph node metastasis

  2023cites this paper
• Gene expression and methylation profiles show the involvement of POMC in primary hyperparathyroidsm

  2022cites this paper
• Is Melanoma Progression Affected by Thyroid Diseases?

  2022cites this paper
• Gene Editing with CRISPR/Cas Methodology and Thyroid Cancer: Where Are We?

  2022cites this paper
• New Insights into the Link between Melanoma and Thyroid Cancer: Role of Nucleocytoplasmic Trafficking

  2021cites this paper
• Papillary Thyroid Cancer Prognosis: An Evolving Field

  2021cites this paper
• Therapeutic Strategy in Low-Risk Papillary Thyroid Carcinoma – Long-Term Results of the First Single-Center Prospective Non-Randomized Trial Between 2011 and 2015

  2021cites this paper
• Clinical efficacy with dabrafenib and trametinib in a T599_V600insT poorly differentiated metastatic thyroid carcinoma

  2021cites this paper
• NTRK Fusion Genes in Thyroid Carcinomas: Clinicopathological Characteristics and Their Impacts on Prognosis

  2021cites this paper
• Molecular Genetics of Follicular-Derived Thyroid Cancer

  2021cites this paper
• Emerging systemic antitarget treatment for differentiated thyroid carcinoma

  2021influential citation
• Genetic Profiles of Aggressive Variants of Papillary Thyroid Carcinomas

  2021cites this paper
• Molecular Pathology of Non-familial Follicular Epithelial–Derived Thyroid Cancer in Adults: From RAS/BRAF-like Tumor Designations to Molecular Risk Stratification

  2021cites this paper
• A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer

  2021cites this paper
• Alterations of regulatory factors and DNA methylation pattern in thyroid cancer

  2020cites this paper
• [Tumors of the thyroid gland. Proposal for the management and study of samples from patients with thyroid neoplasms].

  2020cites this paper
• BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates

  2020cites this paper
• TERT Promoter Mutations and Their Impact on Gene Expression Profile in Papillary Thyroid Carcinoma

  2020cites this paper
• Differences in Gene Expression Profile of Primary Tumors in Metastatic and Non-Metastatic Papillary Thyroid Carcinoma—Do They Exist?

  2020cites this paper
• Development and Validation of a Risk Scoring System Derived from Meta-Analyses of Papillary Thyroid Cancer

  2020cites this paper
• Identification of a Prognostic 3-Gene Risk Prediction Model for Thyroid Cancer

  2020cites this paper
• Thyroid Papillary Microtumor

  2020cites this paper
• S616-p-DRP1 associates with locally invasive behavior of follicular cell-derived thyroid carcinoma

  2020cites this paper
• Pitfalls in RET fusion detection using break-apart FISH probes in papillary thyroid carcinoma.

  2020cites this paper
• Study of BRAF and RAS Mutations in Thyroid Nodules with Indeterminate Cytology and Papillary Thyroid Cancer

  2020cites this paper
• Thyroid Cancer Brain Metastasis: Survival and Genomic Characteristics of a Large Tertiary Care Cohort.

  2019cites this paper
• Original tumour suppressor gene polycystic kidney and hepatic disease 1-like 1 is associated with thyroid cancer cell progression

  2019cites this paper
• Staging and Prognosis of Thyroid Cancer

  2019cites this paper
• Prognostic significance of TERT promoter and BRAF mutations in TIR-4 and TIR-5 thyroid cytology.

  2019cites this paper
• Heat shock proteins in thyroid malignancies: Potential therapeutic targets for poorly-differentiated and anaplastic tumours?

  2019cites this paper
• Incidence of BRAF V600E mutation in patients with papillary thyroid carcinoma: a single-institution experience

  2019cites this paper
• Relationship between genetic alterations and clinicopathological characteristics of papillary thyroid carcinoma

  2019cites this paper
• PD-1 Ligand Expression in Epithelial Thyroid Cancers: Potential Clinical Implications

  2019cites this paper
• BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future Perspectives

  2019cites this paper
• Role of differentially expressed genes and long non‐coding RNAs in papillary thyroid carcinoma diagnosis, progression, and prognosis

  2018cites this paper
• Rare Tumors of the Thyroid Gland

  2018cites this paper
• Kallikreins Stepwise Scoring Reveals Three Subtypes of Papillary Thyroid Cancer with Prognostic Implications

  2018cites this paper
• Oncogenic mutations in KEAP1 disturbing inhibitory Nrf2‐Keap1 interaction: Activation of antioxidative pathway in papillary thyroid carcinoma

  2018cites this paper
• Frecuencia de la mutación Brafv600e, el patrón de metilación en Rassf1a y la expresión de Nis en carcinoma papilar de tiroides

  2018influential citation
• Salivary Gland, Thyroid, and Parathyroid Neoplasms: Molecular Features

  2018cites this paper
• Rare Papillary Thyroid Carcinomas

  2018cites this paper
• mRNA Expression of SLC5A5 and SLC2A Family Genes in Papillary Thyroid Cancer: An Analysis of The Cancer Genome Atlas

  2018cites this paper
• Identification of Biomarkers Based on Differentially Expressed Genes in Papillary Thyroid Carcinoma

  2018cites this paper
• Unravelling the role of fatty acid metabolism in cancer through the FOXO3-FOXM1 axis.

  2017cites this paper
• Aggressiveness of the tall cell variant of papillary thyroid carcinoma is independent of the tumor size and patient age

  2017cites this paper
• Molecular Markers Involved in Tumorigenesis of Thyroid Carcinoma: Focus on Aggressive Histotypes

  2017influential citation
• TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease

  2017cites this paper
• Nueva generación de biomarcadores epigenéticos y transcriptómicos en el cáncer de tiroides bien diferenciado

  2017cites this paper
• The pathogenic role of mTOR pathway in papillary thyroid carcinoma and its impact on sodium iodide symporter (NIS) expression

  2017cites this paper
• Role of mitochondrial dynamics in Hürthle cell tumours: Coupling, uncoupling and fission

  2017influential citation
• Hobnail Variant of Papillary Thyroid Carcinoma: Clinicopathologic and Molecular Evidence of Progression to Undifferentiated Carcinoma in 2 Cases

  2017cites this paper
• Ectopic Thyroid Tissue: Immunohistochemistry and Molecular Analysis

  2017cites this paper
• Upregulated LAMB3 increases proliferation and metastasis in thyroid cancer

  2017cites this paper
• The Role of BEAMing and Digital PCR for Multiplexed Analysis in Molecular Oncology in the Era of Next-Generation Sequencing

  2017cites this paper
• Current Advances in Thyroid Cancer Management. Are We Ready for the Epidemic Rise of Diagnoses?

  2017cites this paper
• RET/PTC3 Rearrangement in Papillary Thyroid Carcinoma: Possible Marker of Tumor Progression.

  2017cites this paper
• Protein molecular modeling of genetic markers for thyroid cancer

  2016cites this paper
• Genomic Profiling of Thyroid Cancer Reveals a Role for Thyroglobulin in Metastasis.

  2016cites this paper
• Identification of CHEK1, SLC26A4, c-KIT, TPO and TG as new biomarkers for human follicular thyroid carcinoma

  2016cites this paper
• Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAFV600E Harboring Pediatric Papillary Thyroid Carcinomas

  2016cites this paper
• PREDICTIVE VALUE OF SOMATIC MUTATIONS FOR THE DEVELOPMENT OF MALIGNANCY IN THYROID NODULES BY CYTOPATHOLOGY.

  2016cites this paper